JUL 09, 2019 10:33 AM PDT

Effective Treatment for Ulveal Melanoma

WRITTEN BY: Nouran Amin

Ulveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly half of these diagnoses will go on to develop metastatic uveal melanoma that will target other parts of the body—mainly the liver. Prognosis is often poor with a median survival of 17 to 20 months. However, researchers have now identified a drug combination designed to target the metastatic uveal melanoma cells in preclinical studies

Learn more about uveal melanoma:

Researchers have designed uveal melanoma cell lines that were resistant to MEK inhibitors—drugs that target the MEK protein implicated in MAPK signaling of melanoma patients—and performed proteomic analysis to examine what signaling pathways were activated during the MEK inhibitor resistance process.

“We identified a number of putative escape pathways that were upregulated following MEK inhibition, including the PI3K/AKT pathway, ROR1/2 and IGF-1R signaling,” explained Keiran Smalley, PhD, director of Moffitt’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence.

Researchers were hopeful that through the identification of critical signaling pathways, they can understand how uveal melanoma cells become resistant to treatment and then counteract with an additional drug alongside MEK inhibitors.

Findings were published in Clinical Cancer Research and reveal that histone deacetylase (HDAC) inhibitors drugs, particularly panobinostat, were most effective in targeting two critical pathways in the resistance process: AKT and YAP signaling.

“Our finding that a clinically approved pan-HDAC inhibitor was effective at simultaneously limiting YAP and AKT signaling in uveal melanoma cells suggests this could be a good candidate for future clinical development,” explained Smalley.

In mouse studies, these results indicate a successful combination treatment with HDAC panobinostat along with and the MEK inhibitor trametinib is effective at uveal melanoma tumor growth reduction.

Source: Moffitt Cancer Center

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 24, 2019
Microbiology
JUL 24, 2019
Fecal Transplants Recommended for Recurrent C. diff Infections
While hospitals are intended to be places of healing, people can acquire nasty infections with drug-resistant bacteria during a stay there....
JUL 24, 2019
Drug Discovery
JUL 24, 2019
First PI3K Inhibitor for Breast Cancer
The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant fo...
JUL 24, 2019
Health & Medicine
JUL 24, 2019
Formation of Habitual Cannabis Use Drives Addiction
According to a new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier, shifting from brain systems controlling...
JUL 24, 2019
Drug Discovery
JUL 24, 2019
Promising Hypertension Drug for Alzheimer Disease
In a study led by the American Heart Association, the blood pressure drug nilvadipine (a calcium channel blocker) was found to increase blood flow to the b...
JUL 24, 2019
Drug Discovery
JUL 24, 2019
Drug Compound May Treat Common Genetic Kidney Disease
Researchers from the University of Sheffield in collaboration with Glasgow-based biotech company Mironid, have developed a new class of drugs for treating ...
JUL 24, 2019
Health & Medicine
JUL 24, 2019
FDA Approves Vyleesi - "The Female Viagra" for Premenopausal Women
Last Friday, the FDA approved a new drug that some are referring to as “the female Viagra.” Vyleesi, the drug’s market name, is injectabl...
Loading Comments...